Citations

Clear

382 citation(s) found for "Li, Man".

Impaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans
Sharma, Anu , Varghese, Ron T. , Man, Chiara Dalla , Rizza, Robert A., Bailey, Kent R. , Dalla Man, Chiara , Shah, Mithun V , Cobelli, Claudio , Vella, Adrian

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 6, 2017 | Volume: 103 | Issue: 1 | Pages: 314-319

10.1210/jc.2017-01197 | PMID 29126197 Get It

Abstract Context Abnormal glucagon concentrations contribute to hyperglycemia, but the mechanisms of α-cell dysfunction in prediabetes are unclear. Objective We sought to determine the relative contributions of insulin secretion and action to α-cell dysfunction in nondiabetic participants across the spectrum of glucose tolerance. Design This was a cross-sectional study. A subset of participants (n = 120) was studied in the presence and absence of free fatty acid (FFA) elevation, achieved by infusion of Intralipid (Baxter Healthcare, Deerfield, IL) plus heparin, to cause insulin resistance. Setting An inpatient clinical research unit at an academic medical center. Participants A total of 310 nondiabetic persons participated in this study. Interventions Participants underwent a seven-sample oral glucose tolerance test. Subsequently, 120 participants were studied on two occasions. On one day, infusion of Intralipid plus heparin raised FFA. On the other day, participants received glycerol as a control. Main Outcome Measure(s) We examined the relationship of glucagon concentration with indices of insulin action after adjusting for the effects of age, sex, and weight. Subsequently, we sought to determine whether an acute decrease in insulin action, produced by FFA elevation, altered glucagon concentrations in nondiabetic participants. Results Fasting glucagon concentrations correlated positively with fasting insulin and C-peptide concentrations and inversely with insulin action. Fasting glucagon was not associated with any index of β-cell function in response to an oral challenge. As expected, FFA elevation decreased insulin action and also raised glucagon concentrations. Conclusions In nondiabetic participants, glucagon secretion was altered by changes in insulin action.
Historical epidemiology of hepatitis C virus in select countries—volume 4
Vince, Adriana , Himatt, Sayed , Mohamed, Rosmawati , Opare‐Sem, Ohene , Workneh, A., Njouom, Richard , Ghazzawi, Imad, Abdulla, Maheeba , Kaliaskarova, Kulpash , Owusu‐Ofori, Shirley , Abdelmageed, Marwa , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Kaabi, S. Al, Naamani, Khalid Al , Qamish, Jehad Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Busafi, Said A. , Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Bane, Abate, Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Cardenas, I., Chan, Henry Lik‐Yuen , Chen, C. J., Chen, Ding‐Shinn , Chen, Pei‐Jer , Cuellar, Diego , Derbala, M., Elbardiny, A. A., Estes, Chris , Farag, E., Gamkrelidze, Ivane , Garcìa, V. , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Hamoudi, Waseem , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee Tak , Jahis, Rohani, Jelev, Deian, John, Anil K , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Layden, Jennifer E. , Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching‐kong, Lukšić, Boris, Malu, Abraham O., Mateva, Lyudmila, Mitova, R, Morović, Miro, Murphy, K., Mustapha, B., Nde, H. , Nersesov, Alexander , Ngige, Evelyn, Njoya, Oudou, Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omede, O. , Omuemu, C., Phillips, Richard Odame , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Redae, Berhane, Reić, Tatjana, Wit, Tobias Rinke de, Ríos, Cielo , Robbins, S., Roberts, Lewis R. , Sanad, S. J., Schmelzer, Jonathan, Sharma, Manik , Simonova, Marieta, Su, Tung‐Hung , Sultan, K., Tan, S. S. , Tchernev, К., Tsang, O. T. Y., Tsang, S., Tzeuton, Christian, Ugoeze, S., Vi, R., Wani, Hamid, Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Razavi‐Shearer, Kathryn , Wong, Grace Lai‐Hung , Roberts, Lewis R , Fung, James , Akın, Onur , Blach, Sarah , Chien, Rong‐Nan , Chuang, Wan‐Long , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 8-24

10.1111/jvh.12762 | PMID 29105285 Get It

SummaryDue to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials to develop or adapt national hepatitis C virus (HCV) control strategies to the changing epidemiological landscape. To do so, detailed, country‐specific data are needed to characterize the burden of chronic HCV infection. In this study of 17 countries, a literature review of published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates was conducted, and inputs were validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Hong Kong to 2.4% in Taiwan, while the largest viraemic populations were in Nigeria (2 597 000 cases) and Taiwan (569 000 cases). Diagnosis, treatment and liver transplant rates varied widely across the countries included in this analysis, as did the availability of reliable data. Addressing data gaps will be critical for the development of future strategies to manage and minimize the disease burden of hepatitis C.
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4
Chan, Henry Lik‐Yuen , Chen, C. J., Omede, O. , Qamish, Jehad Al, Naamani, Khalid Al , Bane, Abate, Tan, S. S. , Simonova, Marieta, Cardenas, I., Derbala, Moutaz , Phillips, Richard Odame , Abdelmageed, Marwa , Abdulla, Maheeba , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Ghazzawi, Imad, Kaabi, S. Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Busafi, Said A. , Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Blach, Sarah , Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Chen, Ding‐Shinn , Chen, Pei‐Jer , Cuellar, Diego , Elbardiny, A. A., Farag, Elmoubasher , Gamkrelidze, Ivane , Garcìa, V. , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Hamoudi, Waseem , Himatt, Sayed , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee Tak , Jahis, Rohani, Jelev, Deian, John, Anil K , Kaliaskarova, Kulpash , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Layden, Jennifer E. , Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching Kong, Lukšić, Boris, Maaroufi, Abderrahmane , Malu, Abraham O., Mateva, Lyudmila, Mitova, R, Mohamed, Rosmawati , Morović, Miro, Murphy, K., Mustapha, B., Nersesov, Alexander , Ngige, Evelyn, Njouom, Richard , Njoya, Oudou, Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omuemu, C., Opare‐Sem, Ohene , Owusu‐Ofori, Shirley , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Razavi‐Shearer, Kathryn , Redae, Berhane, Reić, Tatjana, Wit, Tobias Rinke de, Ríos, Cielo , Robbins, S., Roberts, Lewis R. , Sanad, S. J., Schmelzer, Jonathan, Sharma, Manik , Su, Tung‐Hung , Sultan, K., Tchernev, К., Tsang, O. T. Y., Tsang, Simon H. Y., Tzeuton, Christian, Ugoeze, S., Vi, R., Vince, Adriana , Wani, Hamid, Workneh, A., Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Nde, H. , Wong, Grace Lai‐Hung , Blach, S , Roberts, Lewis R , Akın, Onur , Chien, Rong‐Nan , Chuang, Wan‐Long , Estes, Chris , Fung, James , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 25-43

10.1111/jvh.12760 | PMID 29105283 Get It

SummaryFactors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time and place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar and Taiwan) to quantify and characterize the viremic population as well as forecast the changes in the infected population and the corresponding disease burden from 2015 to 2030. Model inputs were agreed upon through expert consensus, and a standardized methodology was followed to allow for comparison across countries. The viremic prevalence is expected to remain constant or decline in all but four countries (Ethiopia, Ghana, Jordan and Oman); however, HCV‐related morbidity and mortality will increase in all countries except Qatar and Taiwan. In Qatar, the high‐treatment rate will contribute to a reduction in total cases and HCV‐related morbidity by 2030. In the remaining countries, however, the current treatment paradigm will be insufficient to achieve large reductions in HCV‐related morbidity and mortality.
Strategies to manage hepatitis C virus infection disease burden—Volume 4
Chen, Ding‐Shinn , Hamoudi, Waseem , Mustapha, B., Layden, Jennifer E. , Nersesov, Alexander , Reić, Tatjana, Garcìa, V. , Ríos, Cielo , Mateva, Lyudmila, Njoya, Oudou, Al‐Busafi, Said A. , Abdelmageed, Marwa , Abdulla, Maheeba , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Ghazzawi, Imad, Kaabi, S. Al, Naamani, Khalid Al , Qamish, Jehad Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Bane, Abate, Blach, Sarah , Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Cardenas, I., Chan, Henry Lik‐Yuen , Chen, C. J., Chen, Pei‐Jer , Cuellar, Diego , Derbala, M., Elbardiny, A. A., Farag, E., Gamkrelidze, Ivane , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Himatt, Sayed , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee‐Tak, Jahis, Rohani, Jelev, Deian, John, Anil K , Kaliaskarova, Kulpash , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching‐kong, Lukšić, Boris, Maaroufi, Abderrahmane , Malu, Abraham O., Mitova, R, Mohamed, Rosmawati , Morović, Miro, Murphy, K., Nde, H. , Ngige, Evelyn, Njouom, Richard , Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omede, O. , Omuemu, C., Opare‐Sem, Ohene , Owusu‐Ofori, Shirley , Phillips, Richard Odame , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Razavi‐Shearer, Kathryn , Redae, Berhane, Wit, Tobias Rinke de, Robbins, S., Roberts, Lewis R. , Sanad, S. J., Sharma, Manik , Simonova, Marieta, Su, Tung‐Hung , Sultan, K., Tan, S. S. , Tchernev, К., Tsang, O. T. Y., Tsang, Simon H. Y., Tzeuton, Christian, Ugoeze, S., Vi, R., Vince, Adriana , Wani, Hamid, Workneh, A., Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Schmelzer, Jonathan, Hui, Yee Tak , Wong, Grace Lai‐Hung , Blach, S , Roberts, Lewis R , Akın, Onur , Chien, Rong‐Nan , Chuang, Wan‐Long , Estes, Chris , Fung, James , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 44-63

10.1111/jvh.12759 | PMID 29105286 Get It

SummaryThe hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets—“WHO Targets” (65% reduction in HCV‐related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies. The scenarios developed to achieve the WHO Targets in all countries studied assumed the implementation of national policies to prevent new infections and to diagnose current infections through screening.
Clinical Reasoning: A 46-year-old man with persistent hiccups, cognitive dysfunction, and imbalance
Lamb, Christopher J. , López‐Chiriboga, A. Sebastian , Mendez, Julio, Robinson, Maisha T. , Sotello Aviles, David A , Mendez, Julio C, Lamb, Christopher J , Sotello, David

Mayo Clinic

Neurology | October 16, 2017 | Volume: 89 | Issue: 16 | Pages: No page available

10.1212/wnl.0000000000004523 | PMID 29038139 Get It

A CONSTANT-RATE INDICATOR-INFUSION TECHNIC FOR THE MEASUREMENT OF CENTRAL VASCULAR VOLUME IN MAN
Bowers, Dorrance, Shepherd, John T., Wood, Earl H.

Mayo Clinic

Canadian Journal of Biochemistry and Physiology | October 16, 2017 | Volume: 33 | Issue: 1 | Pages: 340-348

10.1139/y55-045 Get It

Evans blue dye was injected at a constant rate into the right ventricle or pulmonary artery of 17 subjects in 21 experiments. The consequent arterial dilution patterns were recorded continuously by a cuvette oximeter connected to an indwelling needle in the radial artery. From these dilution patterns the amount and concentration of dye in the intravascular space between the injecting and sampling sites were determined when an equilibrium concentration was attained. From these dimensions the "central vascular volume" was calculated. The values for the central vascular volume thus derived showed agreement with those determined in near-simultaneous estimations by Hamilton's modification of Stewart's method. The values for the "lung blood volumes" by the Newman method in these subjects were systematically smaller than the values for the central vascular volume.
Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia
Dassau, Eyal , Pinsker, Jordan E. , Kudva, Yogish C. , Brown, Sue A. , Gondhalekar, Ravi , Man, Chiara Dalla , Patek, Steve, Schiavon, Michele , Dadlani, Vikash, Dasanayake, Isuru , Church, Mei Mei , Carter, Rickey E. , Bevier, Wendy C. , Huyett, Lauren M. , Hughes, Jonathan , Anderson, Stacey M. , Lv, Dayu, Schertz, Elaine, Emory, Emma, McCrady-Spitzer, Shelly , Jean, Tyler, Bradley, Paige K., Hinshaw, Ling , Sanz, Alejandro José Laguna , Basu, Ananda , Kovatchev, Boris , McCrady-Spitzer, Shelly K, Cobelli, Claudio , Doyle, Francis J , Dalla Man, Chiara , Carter, Rickey E , Kovatchev, Boris , Cobelli, Claudio , Doyle, Francis J. , Schiavon, Michele

Mayo Clinic

Diabetes Care | October 14, 2017 | Volume: 40 | Issue: 12 | Pages: 1719-1726

10.2337/dc17-1188 | PMID 29030383 Get It

OBJECTIVE Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks. RESEARCH DESIGN AND METHODS Thirty adults with T1D completed a continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the AP was started, basal insulin delivery settings used by the AP for initialization were adapted weekly, and carbohydrate ratios were adapted every 4 weeks by an algorithm running on a cloud-based server, with automatic data upload from devices. Adaptations were reviewed by expert study clinicians and patients. The primary end point was change in hemoglobin A1c (HbA1c). Outcomes are reported adhering to consensus recommendations on reporting of AP trials. RESULTS Twenty-nine patients completed the trial. HbA1c, 7.0 ± 0.8% at the start of AP use, improved to 6.7 ± 0.6% after 12 weeks (−0.3, 95% CI −0.5 to −0.2, P < 0.001). Compared with the SAP run-in, CGM time spent in the hypoglycemic range improved during the day from 5.0 to 1.9% (−3.1, 95% CI −4.1 to −2.1, P < 0.001) and overnight from 4.1 to 1.1% (−3.1, 95% CI −4.2 to −1.9, P < 0.001). Whereas carbohydrate ratios were adapted to a larger extent initially with minimal changes thereafter, basal insulin was adapted throughout. Approximately 10% of adaptation recommendations were manually overridden. There were no protocol-related serious adverse events. CONCLUSIONS Use of our novel adaptive AP yielded significant reductions in HbA1c and hypoglycemia.
Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma
Pašić, Ivan , Wong, Kit Man , Lee, Jonghun J., Espin‐Garcia, Osvaldo , Brhane, Yonathan , Cheng, Dangxiao , Patel, Devalben, Brown, Catherine , Bucur, Roxana , Reisman, David , Knox, Jennifer J. , Hung, Rayjean J., Liu, Geoffrey , Cleary, Sean P. , Hung, Rayjean J. , Hung, Rayjean J , Liu, Geoffrey , Cleary, Sean P , Chen, Zhuo , Xu, Wei , Knox, Jennifer J

Mayo Clinic

Molecular Carcinogenesis | September 11, 2017 | Volume: 57 | Issue: 1 | Pages: 106-113

10.1002/mc.22736 | PMID 28892201 Get It

Polymorphisms in the promoter of the BRM gene, a critical subunit of the chromatin remodeling SWI/SNF complex, have previously been implicated in risk and prognosis in Caucasian‐predominant lung, head and neck, esophageal, and pancreatic cancers, and in hepatocellular cancers in Asians. We investigated the role of these polymorphisms in hepatocellular carcinoma (HCC) risk and prognosis. HCC cases were recruited in a comprehensive cancer center while the matched controls were recruited from family practice units from the same catchment area. For risk analyses, unconditional logistic regression analyses were performed in HCC patients and matched healthy controls. Overall survival analyses were performed using Cox proportional hazard models, Kaplan‐Meier curves, and log‐rank tests. In 266 HCC cases and 536 controls, no association between either BRM promoter polymorphism (BRM‐741 or BRM‐1321) and risk of HCC was identified (P > 0.10 for all comparisons). There was significant worsening of overall survival as the number of variant alleles increased: BRM‐741 per variant allele adjusted hazards ratio (aHR) 5.77, 95% confidence interval (CI) 2.89‐11.54 and BRM‐1321 per variant allele aHR 4.09, 95%CI 2.22‐7.51. The effects of these two polymorphisms were at least additive, where individuals who were double homozygotes for the variant alleles had a 45‐fold increase in risk of death when compared to those who were double wild‐type for the two polymorphisms. Two BRM promoter polymorphisms were strongly associated with HCC prognosis but were not associated with increased HCC susceptibility. The association was strongest in double homozygotes for the allele variants.
Performance of individually measured vs population‐based C ‐peptide kinetics to assess β‐cell function in the presence and absence of acute insulin resistance
Varghese, Ron T. , Man, Chiara Dalla , LAURENTI, MARCELLO C. , Piccinini, Francesca, Sharma, Anu , Bailey, Kent R. , Rizza, Robert A., Vella, Adrian , Vella, Adrian , Dalla Man, Chiara , Shah, Mithun V , Cobelli, Claudio

Mayo Clinic

Diabetes, Obesity and Metabolism | September 1, 2017 | Volume: 20 | Issue: 3 | Pages: 549-555

10.1111/dom.13106 | PMID 28862812 Get It

Aims To compare the performance of population‐based kinetics with that of directly measured C‐peptide kinetics when used to calculate β‐cell responsivity indices, and to study people with and without acute insulin resistance to ensure that population‐based kinetics apply to all conditions where β‐cell function is measured. Methods Somatostatin was used to inhibit endogenous insulin secretion in 56 people without diabetes. Subsequently, a C‐peptide bolus was administered and the changing concentrations were used to calculate individual kinetic measures of C‐peptide clearance. In addition, the participants were studied on 2 occasions in random order using an oral glucose tolerance test (OGTT). On one occasion, free fatty acid elevation, to cause insulin resistance, was achieved by infusion of Intralipid + heparin. The Disposition Index (DI) was then estimated by the oral minimal model using either population‐based or individual C‐peptide kinetics. Results There were marked differences in the exchange variables ( k 12 and k 21 ) of the model describing C‐peptide kinetics, but smaller differences in the fractional clearance; that is, the irreversible loss from the accessible compartment ( k 01 ), obtained from population‐based estimates compared with experimental measurement. Because it is predominantly influenced by k 01 , DI estimated using individual kinetics correlated well with DI estimated using population‐based kinetics. Conclusions These data support the use of population‐based measures of C‐peptide kinetics to estimate β‐cell function during an OGTT.
An Elderly Man With a Pacemaker and a Recent Fall
Morales-Lara, Andrea Carolina , Leoni, Juan , Morales-Lara, A Carolina, Leoni, Juan C, Kusumoto, Fred M, Leoni, Juan Carlos , Kusumoto, Fred

Mayo Clinic

JAMA Cardiology | August 25, 2017 | Volume: 2 | Issue: 10 | Pages: 1161

10.1001/jamacardio.2017.1932 | PMID 28832863 Get It